You are here: Home » Current Affairs » Coronavirus » News
Coronavirus update: Karnataka govt issues new guidelines for home isolation
CBI files case against Punjab Basmati Rice Ltd on complaint of Canara Bank
Business Standard

Now, Zydus Cadila gets DCGI nod for human trials of Covid vaccine

Zydus Cadila has already successfully completed preclinical phase for its plasmid DNA vaccine candidate ZyCoV-D developed indigenously at its Vaccine Technology Centre in Ahmedabad

Topics
Coronavirus Vaccine | Coronavirus | Zydus Cadila

Vinay Umarji  |  Ahmedabad 



vaccine, pharma, coronavirus, medicine, drugs, medical research, covid, lab
Zydus Cadila intends to now rapidly ramp up the production capacities of ZyCoV-D at multiple sites and facilities to cater to Indian and global demand

After Bharat Biotech, now Ahmedabad-based drug major Cadila Healthcare Ltd (Zydus Cadila) has bagged the Drug Controller General of India (DCGI)'s - Central Drugs Standard Control Organisation (CDSCO) nod for initiating phase-I/II human for its Covid-19 vaccine.

TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.

SUBSCRIBE TO INSIGHTS

What you get on Business Standard Premium?

  • icon Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • icon Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • icon Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
  • icon Pick your 5 favourite companies, get a daily email with all news updates on them.
  • icon 26 years of website archives.
  • icon Preferential invites to Business Standard events.

OR

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.


We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, July 03 2020. 10:30 IST

RECOMMENDED FOR YOU